STOCK TITAN

Bright Minds Biosciences (DRUG): Cormorant Asset Management reports 9.17% ownership stake

(Moderate)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Cormorant Asset Management, LP and Bihua Chen report a significant ownership stake in Bright Minds Biosciences Inc. They report beneficial ownership of 900,000 Common Shares, representing 9.17% of the class, based on 9,812,061 Common Shares outstanding as of May 15, 2026.

The shares are held by certain Cormorant funds, with the Reporting Persons having shared voting power over 900,000 shares and shared dispositive power over 900,000 shares, and no sole voting or dispositive power. Cormorant Global Healthcare Master Fund, LP has the right to receive dividends or sale proceeds from more than 5% of the shares.

Positive

  • None.

Negative

  • None.
Shares beneficially owned 900,000 shares Common Shares of Bright Minds Biosciences beneficially owned by the Reporting Persons
Percent of class 9.17% Ownership percentage of Bright Minds Biosciences Common Shares
Shares outstanding 9,812,061 shares Common Shares outstanding as of May 15, 2026 used for the ownership calculation
Shared voting power 900,000 shares Shares over which the Reporting Persons have shared power to vote or direct the vote
Shared dispositive power 900,000 shares Shares over which the Reporting Persons have shared power to dispose or direct disposition
Sole voting power 0 shares Shares over which the Reporting Persons have sole power to vote
Sole dispositive power 0 shares Shares over which the Reporting Persons have sole power to dispose
beneficial owner regulatory
"the beneficial owner of the shares reported herein"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
shared voting power regulatory
"Shared Voting Power 900,000.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"Shared Dispositive Power 900,000.00"
percent of class financial
"Percent of class: 9.17%"
Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.
Report of Foreign Private Issuer regulatory
"attached as Exhibit 99.2 to the Report of Foreign Private Issuer on Form 6-K"
A report of a foreign private issuer is a formal filing that a non‑U.S. company makes to U.S. regulators to share important business, financial, or governance information with American investors. Think of it as a regular update or press packet that keeps investors informed about events that could change a company’s value—like earnings, management changes, contracts, or regulatory developments—so investors can make timely, informed decisions.
investment adviser financial
"the investment adviser to certain funds (the "Cormorant Funds")"
An investment adviser is a person or firm that professionally manages money and gives recommendations about buying, selling, or holding investments. Like a financial coach or guide, they have a legal duty to act in a client's best financial interest, so their advice, fees and potential conflicts can directly affect returns and risk — making their role important for investors who want informed, accountable help with portfolios.

FAQ

What percentage of Bright Minds Biosciences (DRUG) does Cormorant Asset Management report owning?

Cormorant Asset Management and Bihua Chen report beneficial ownership of 9.17% of Bright Minds Biosciences’ Common Shares, representing 900,000 shares out of 9,812,061 shares outstanding as of May 15, 2026.

How many Bright Minds Biosciences (DRUG) shares are beneficially owned by the Reporting Persons?

The Reporting Persons state they beneficially own 900,000 Common Shares of Bright Minds Biosciences. This stake is calculated as 9.17% of the class, using 9,812,061 shares outstanding as of May 15, 2026 as the reference.

What voting and dispositive power does Cormorant have over Bright Minds Biosciences (DRUG) shares?

The Reporting Persons report 0 shares with sole voting or dispositive power and 900,000 shares with shared voting power and shared dispositive power. This means decisions are made jointly regarding voting and potential sale of these shares.

Which entity within Cormorant holds more than 5% of Bright Minds Biosciences (DRUG)?

Cormorant Global Healthcare Master Fund, LP, a Cormorant Fund, is identified as having the right to receive or direct dividends or sale proceeds from more than 5% of Bright Minds Biosciences’ Common Shares reported in this statement.

Who are the Reporting Persons in the Bright Minds Biosciences (DRUG) ownership filing?

The filing identifies Cormorant Asset Management, LP, a Delaware limited partnership and investment adviser to certain funds, and Bihua Chen as the Reporting Persons with respect to the 900,000 Common Shares held by the Cormorant Funds.

On what share count is the 9.17% Bright Minds Biosciences (DRUG) ownership calculation based?

The 9.17% ownership is based on a reported total of 9,812,061 Common Shares outstanding as of May 15, 2026, as stated in Bright Minds Biosciences’ Management Discussion and Analysis referenced in a Form 6-K.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





10919W405

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Cormorant Asset Management, LP
Signature:/s/ Bihua Chen
Name/Title:Bihua Chen, Managing Member
Date:08/14/2026
Bihua Chen
Signature:/s/ Bihua Chen
Name/Title:Bihua Chen
Date:08/14/2026
Exhibit Information

Joint Filing Statement, incorporated by reference to the Joint Filing Statement included with the Schedule 13G filed by the Reporting Persons on October 22, 2024.